Antibodies are powerful preventive and therapeutic tools against microbes, cancers, autoimmune disorders, and many other diseases. However, traditional antibody discovery approaches often face major limitations, including low efficiency, high costs, high failure rates, logistical barriers, limited scalability, and long turnaround times.
In this webinar, Dr. Georgiev will discuss progress toward developing and validating integrated platforms for antibody discovery. He will highlight how these approaches can transform both the process and cost of identifying new monoclonal antibody drug candidates, while enabling the discovery of antibody phenotypes that have been challenging or even impossible to achieve using traditional methods.
Key points to be discussed during the session:
- How wet-lab and AI-based platforms can improve efficiency, scalability, and success rates in antibody discovery
- How integrated computational and experimental workflows can reduce cost, complexity, and turnaround time
- How next-generation platforms can uncover antibody phenotypes that traditional methods often miss
